Metastatic Lymph Node Distribution in the Ileum Mesentery of Cecal and Proximal Ascending Colon Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Experimental.
- Who it may be relevant to
- Registry conditions: Colon Cancer. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Prospective Multicenter Observational Study on Metastatic Lymph Node Distribution of Ileum Mesentery in Cecal Cancer and Proximal Ascending Colon Cancer
Overview
Based on the above considerations, our team maintains that it is currently imperative to conduct a prospective multicenter registry study. This study would involve sectioning and submitting fresh surgical specimens from the ileum mesentery of patients undergoing radical resection for cecal cancer and proximal ascending colon cancer (right-sided colon cancer). The objectives are to: Clarify the distribution range of metastatic lymph nodes within the ileum mesentery; Conduct survival follow-up on enrolled patients; Provide reliable evidence-based medical evidence for the individualized determination of ileal resection margins.
Interventions
- Procedure Experimental
sectioning and submitting fresh surgical specimens from the ileum mesentery
Primary outcome measures
- Metastatic rate in mesenteric lymph nodes [Time frame: 1 month after surgery]
Secondary outcome measures (3)
- Distribution of metastatic lymph nodes in the mesentery [Time frame: 1 month after surgery]
- 3-year disease-free survival [Time frame: 3 years after surgery]
- 5-year overall survival [Time frame: 5 years after surgery]
Eligibility criteria
Inclusion criteria
Age 18-80 years; ECOG performance status 0-2; Histologically confirmed colon adenocarcinoma; Surgical specimen confirming tumor location at: ileocecal valve orifice (cecal cancer), OR proximal ascending colon cancer with tumor ≤5 cm from ileocecal valve; Clinical stage: cT2-4aN0M0, OR cTanyN+M0; Patient and family members fully understand the study and voluntarily participate by signing informed consent
Exclusion criteria
Synchronous or metachronous multiple primary colon cancers (Note: Synchronous: diagnosed within 6 months; Metachronous: diagnosed >6 months apart); Preoperative neoadjuvant therapy (chemotherapy, immunotherapy, or radiotherapy) that may cause tumor regression or downstaging; Patients undergoing salvage radical surgery after endoscopic resection.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07149623 · RELARC-02